# Clinical Trials Data EGFR - Document 23

# Safety and Preliminary Efficacy of the Treatment of Kidney Allografts With Curcumin-containing Preservation Solution

## Clinical Trial: https://clinicaltrials.gov/study/NCT01285375

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Patients with ESRD assigned for kidney transplantation, written informed consent\n\nExclusion Criteria:\n\n\* None",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, it appears that the trial is specifically for patients with End-Stage Renal Disease (ESRD) who are assigned for kidney transplantation. The criteria do not mention any specific genetic mutations, such as an EGFR gene mutation, as an exclusion criterion or factor for consideration.   
  
Therefore, a patient with an EGFR gene mutation would be eligible for the trial as long as they have ESRD, are assigned for kidney transplantation, are 18 years or older, and meet all other inclusion requirements. It's also important to note that the trial does not accept healthy volunteers, meaning it is intended for individuals with a specific medical condition related to the trial's focus.